Severe pemphigus vulgaris and cervical carcinoma treated with anti PD1 antibody pembrolizumab: A therapeutic dilemma?
Abstract Managing autoimmune diseases (AIDs) in the context of malignancies and vice versa is an intricate challenge for clinicians. Immunotherapies stimulate antitumor immune responses by blocking checkpoint molecules such as PD1. However, new onset or aggravation of autoimmune reactions are freque...
Saved in:
| Main Authors: | Sophia Wasserer, Kristine Mayer, Svenja Rupp, Tilo Biedermann, Oliver J. Stoetzer, Moritz Hamann, Felix Lauffer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.589 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies
by: Qing Zhang, et al.
Published: (2025-04-01) -
Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning
by: Shuxian Pan, et al.
Published: (2025-01-01) -
Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy
by: Caroline J. Cushman, et al.
Published: (2024-11-01) -
Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment
by: John Storwick, et al.
Published: (2025-07-01) -
A Case of Hemophagocytic Lymphohistiocytosis During Immune Checkpoint Inhibitor Treatment for Metastatic Renal Cell Carcinoma, Complicated by Pancytopenia Attributed to Cytomegalovirus Infection
by: Tomoko Honda, et al.
Published: (2025-07-01)